Nordic Bioscience’s Post

If you are at this year's IPF summit, I recommend joining Diana for her talk on #ECM biomarkers for patients with IPF and how these translational biomarkers of fibroblast activity can be utilised in both clinical and preclinical models. One set of biomarkers from in vitro studies to your clinical trials.

GRI Bio, Inc. announced positive preclinical results for their lead program, GRI-0621, targeting Idiopathic Pulmonary Fibrosis (IPF). GRI-0621 is an iNKT cell inhibitor that has shown significant reductions in fibrosis and inflammation in preclinical models. Phase 2a biomarker study data is expected in Q3 2024, with topline results anticipated in Q4 2024. IPF is a challenging condition with limited treatment options, and GRI Bio’s advancements could lead to major improvements in patient outcomes. If you are passionate about contributing to groundbreaking biotech advancements, let's connect. I can help you explore opportunities where your expertise can drive forward innovative treatments. #BiotechCareers #IPF #ClinicalResearch

Congratulations to the finalists in the Alumni & Affiliates Health + Life Sciences Track of the President’s Innovation Challenge. These ventures are driving change in healthcare by developing advanced therapeutic and diagnostic solutions across a spectrum of diseases. Bullseye Biosciences | By leveraging competition and evolution, Bullseye aims to transform therapeutics discovery and expedite the development of life-saving medicines. Ilios Therapeutics | Combating neurodegenerative diseases through rationally-designed multi-functional small molecules. Promakhos Therapeutics | Developing oral, non-immunosuppressive, small molecules to cure chronic inflammatory disorders. Somite Therapeutics | Leveraging AI to develop novel cell therapies for diseases such as diabetes, obesity, and muscular dystrophies. Stratagen Bio | Transforming MRI scans into a tool for objective clinical decision-making and quantitative biomarker assessment. #PIC2024 Watch the awards ceremony livestream on May 1 here: https://bit.ly/44fQDC7

#Researchers, our latest molecule, BI-3404, is a FLT3 activator. This well-characterized humanized antibody is available for a limited time on our open science portal #opnMe. How would you propose to demonstrate a new role for FLT3 activation as a therapeutic concept in novel disease indications?  Submit your innovative research ideas for a chance to access the molecule as well as funding. Learn more on #opnMe and get started! https://lnkd.in/eYuBt7SZ

#StemCells Oral #ALStherapy by #TransposonTherapeutics (TPN-101 PIIa trial) shows safety & slows lung function decline over w/ 1yr’s treatment in ALS C9orf72 mutations. Also see NurOwn PIIIb - Read our #ACFResearch update on $BCLI https://lnkd.in/e2sThM9S The ALS Association ALS TDI

#ASLTreatment - Motor Neuron Disease - recent scientific research showed that Allogeneic B cell immunomodulatory therapy benefitted lab models, i.e. laboratory animals. As a result, the researches got permission from the FDA and Massachusetts General Hospital to try this therapeutic approach in an individual w/ #ALS. There are a range of alternative approaches to developing ALS therapies. We particularly like MSCs including $BCLI's NurOwn, its P3b trial has just begun rollout - of course $BCLI needs further funding to complete, but it is an interesting area with some promise of marked progress in therapy effectiveness for early to mid-stage ALS sufferers, if BCLI's P3b is a success. To see where $BCLI is right now you can read our #ACFResearch #NurOwn Update https://lnkd.in/dFgfxHpk $AZN $AMGN $SNY $GILD $VRTX $ABBV $AMRX $ROG.SW $MRK $PFE $TEVA $NVS $BIIB. Brainstorm Cell Therapeutics Pfizer AbbVie ALS TDI The ALS Association ALS CURE Project

There’s an urgent need for reliable cell models in ALS research. In response to recent clinical trial failures, iPSC technology offers a path forward. A few key points: 🔸 These recent failures underscore a persistent issue in ALS research: the gap between preclinical success and clinical efficacy 🔸 Incorporating relevant biomarkers, like NfL, into the evaluation process can enhance the predictive power of preclinical models 🔸 iPSC technology enables studying the disease in a human context, with key biomarkers, providing more accurate predictions on disease mechanisms and drug responses. Curious to learn more? Check out the new blog from Ncardia in the comments ⬇️ #ALS #drugdiscovery #biomarkers

🌟 The HEALEY Platform Trial: A New Hope for ALS Despite Setbacks 🌟 The HEALEY ALS Platform Trial, launched in 2020, aimed to accelerate the discovery of effective treatments for ALS. While the journey has been challenging, with many investigational therapies missing their primary endpoints, hope persists. This unique trial design, driven by the vision of Sean Healey and Dr. Merit Cudkowicz, has proven the value of quick learning and fast decisions. Although some therapies were discontinued, companies like Clene Nanomedicine, Inc. and Prilenia have moved forward, showing promising data on secondary endpoints, including survival and biomarker improvements. 🔬 Key Highlights: 🧠Clene's CNM-Au8 demonstrated a 49% reduction in mortality risk. 🧠Prilenia's pridopidine showed a promising effect in a subgroup of early-stage ALS patients. 🧠The trial's design allows faster decision-making, with new regimens added in just 30 days. 🧠Though progress has been slower than hoped, the commitment to refining the trial and ongoing participation from companies means we're still moving towards breakthroughs in ALS treatment. #ALS #ClinicalTrials #DrugDevelopment #NeurodegenerativeDiseases #HealthcareInnovation #ALSResearch #HealeyPlatformTrial

Comparing activation methods to yield clinical-scale expansion of γδ #Tcells Some #Tcelltherapies have been approved to treat patients with conditions like #Bcellmalignancies and #multiplemyeloma, but their use for #solidtumors remains challenging. Gamma delta (γδ) T cells have the inherent ability to infiltrate solid tumors and kill transformed cells, but their low prevalence in peripheral blood poses a challenge when generating enough cells to produce a clinical dose. Next month, Lonza Bioscience Solutions’ Chengkang Zhang (Associate Director, R&D) will present two novel methods for the expansion of #gammadeltaTcells from peripheral blood #mononuclearcells (PBMCs) and present data showcasing their suitability for clinical applications Register for this upcoming #webinar below:

Partillion Bioscience has launched an Early Access Program for their new innovative Nanovial Multicell Assays. These new nanovials will unlock they way researchers study cell-to-cell interactions, offering more precise insights into cellular behaviour with a next level of scalability. I had the pleasure of meeting Zuleyma Peralta and the team at FOG Boston, where they shared more about how this platform is accelerating advances in fields like antibody discovery, tumour-immune microenvironment research, and next-gen therapeutics. Nanovials like this could change how multi-omics data is integrated, driving advancements in personalised medicine, drug discovery, and disease research. Interested in joining the Early Access Program? find our more... https://lnkd.in/exZPf9KX #singlecell #genomics #multiuomics